BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Corixa Corporation (CRXA) Announces Fourth Quarter And Year-End 2004 Financial Results


10/19/2005 5:13:00 PM

SEATTLE--(BUSINESS WIRE)--March 14, 2005--Corixa Corporation (Nasdaq:CRXA), a developer of immunotherapeutics, today announced financial results for the fourth quarter and year ended December 31, 2004. For the fourth quarter of 2004, Corixa reported total revenue of $8.3 million compared with total revenue of $12.5 million for the fourth quarter of 2003. Net loss applicable to common stockholders for the fourth quarter of 2004 was $24.8 million, compared with net loss of $16.9 million for the fourth quarter of 2003. Diluted net loss per common share for the fourth quarter of 2004 was $0.42 compared with diluted net loss per common share of $0.31 for the fourth quarter of 2003. Excluding acquisition-related charges, such as intangible and deferred compensation amortization, a lease-related impairment charge and restructuring charges, net loss applicable to common stockholders and diluted net loss per common share for the fourth quarter of 2004 were $20.1 million and $0.34, respectively, compared with net loss applicable to common stockholders and diluted net loss per common share of $14.4 million and $0.26, respectively for the fourth quarter of 2003.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES